Medical Direction In Arizona: The Role and Function of the Medical Director and Pre-Hospital Coordinator in a Challenging Environment - March 10, 2010

View the new page with links to 2009 EMS & Trauma Quality Assurance Conference Presentations.

ATTENTION

EFFECTIVE NOVEMBER 1, 2009, THE FLAGSTAFF BUREAU OF EMS WILL CLOSE.  The Bureau requests that you send all applications and correspondence to the phoenix office at the following mailing address:

BUREAU OF EMS & TRAUMA SYSTEM
150 N 18TH AVENUE, SUITE 540
PHOENIX, ARIZONA 85007

STATEWIDE TOLL FREE NUMBER: 1-800-200-8523
MAIN NUMBER:  602-364-3150
FAX:  602-364-3566.

ADHS has filed a Notice of Exempt Rulemaking to amend R9-25-503, and Table 1, effective January 2, 2009. The purpose of this rulemaking is to add Pralidoxime Chloride Auto-Injectors, Atropine Sulfate Auto-Injectors, and combined Atropine Sulfate and Pralidoxime Chloride Auto-Injectors to the list of agents an EMT may administer or assist a patient to self-administer in the case of a confirmed or suspected neurological toxin release. Pralidoxime Chloride and Atropine Sulfate Auto-Injectors are not currently approved for use by EMTs who would need them in the event of a neurological toxin release. This rulemaking will rectify that situation. The changes in this rulemaking were recommended by the Protocols, Medications, and Devices Committee of the Medical Direction Commission (MDC); the MDC; and the Emergency Medical Services Council. The statute authorizing the exemption from the regular rulemaking process is A.R.S. § 36-2205(C).

ADHS has filed the following Notice of Agency Guidance Documents, effective
March 1, 2010:

• GD-030-PHS-EMS: Drug Profile for Atropine Sulfate
• GD-045-PHS-EMS: Drug Profile for Magnesium Sulfate
• GD-064-PHS-EMS: Arizona Guidelines for Field Triage of Injured Patients and Mode of Transport Considerations
• GD-083-PHS-EMS: Drug Profile for Lorazepam

A copy of each Agency Guidance Document can be found here under Division of Public Health Services.